Project Grant R01HL174961
Award Date
5/1/25
Completion Date
3/31/29
Dollars Obligated
$786K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, supports research on CAMK4 as a regulator of inflammation resolution and trained immunity in atherosclerosis. The primary aims are to explore how trained immunity impairs efferocytosis, a key process in resolving inflammation, and to investigate the role of CAMK4 in trained immunity development. The total award amount is $100,325, provided...
This $715,180 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to understand the epigenetic regulation of trained immunity in thoracic aortic aneurysms and dissections (ATAAD). The project aims to determine the sites and mechanisms of immunity training in monocytes/macrophages, and the role of the STING-IRF3/IRF4 pathway in driving pro-inflammatory macrophage phenotypes during ATAAD...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is focused on studying the molecular mechanisms by which progranulin, an anti-inflammatory protein, regulates endothelial cell function and blood pressure control. The $1,568,003 award, with a project period from September 2024 to April 2029, aims to determine if reduced endothelial progranulin levels contribute to the development and progression of hypertension...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $874,792 to Vanderbilt University Medical Center from July 2024 to June 2028. The project aims to address residual atherosclerotic cardiovascular disease (ASCVD) risk among patients who continue to experience myocardial infarctions or strokes despite treatment to lower LDL-cholesterol and blood pressure. The key objectives are to: (1)...
This federal Project Grant award of $840,873 from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), supports research under the Cardiovascular Diseases Research program (CFDA 93.837). The primary objective is to elucidate the role of epitranscriptional regulation, specifically the N6-methyladenosine (m6A) modification, in endothelial cell function and atherosclerosis development under different blood flow patterns. Key research...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $644,687 to the University of Missouri System to conduct research on a neural circuit that contributes to the cardiovascular responses associated with chronic intermittent hypoxia (CIH), a key characteristic of obstructive sleep apnea. The overarching goal is to understand how a hypothalamic-brainstem circuit involving orexin neurons,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), provides $136,350 to Georgia State University Research Foundation Inc. to investigate the role of arterial baroreceptors in the development of hypertension. The award is funded under the Cardiovascular Diseases Research program (CFDA 93.837), which supports research aimed at understanding, preventing, diagnosing, and treating cardiovascular conditions. The project...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to understand racial/ethnic disparities in clinician concordance with hypertension treatment guidelines and blood pressure control. The total award amount is $727,972.00 and the performance period is from September 1, 2024 through June 30, 2028. The project will utilize data from the Stakeholders, Technology, and Research Clinical...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $167,400 to Brigham & Women's Hospital Inc. to comprehensively investigate how the immune mediator CD70 regulates key endothelial and metabolic pathways related to vascular dysfunction and atherosclerotic cardiovascular disease. The award, effective March 1, 2025 through February 28, 2030, aims to elucidate: 1) CD70 regulation...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $796,083 to Northwestern University to conduct a translational epidemiological study on the relationship between immune cell functional polarization and the progression of atherosclerotic cardiovascular disease (ASCVD). The study aims to investigate single-cell transcriptomic and gene-regulatory profiles of immune cells in...